Navigation Links
Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
Date:6/9/2008

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new Phase I data for the company's diabetes mellitus program at the American Diabetes Association's 68th Scientific Sessions. The data showed that combining the company's proprietary recombinant human hyaluronidase enzyme (rHuPH20) with Humulin R(R) (regular insulin human) or Humalog(R) (insulin lispro) yielded pharmacokinetics and glucodynamics that better mimicked physiologic prandial (mealtime) insulin release and activity than Humulin R or Humalog alone.

Key pharmacokinetic (PK) and glucodynamic (GD) improvements observed in the study include:
-- Significantly faster systemic absorption of each insulin, starting with

the first observation time point of three minutes after injection

-- Significantly faster and greater glucose lowering activity early after

injection

-- Significantly greater peak insulin levels for the same dose

administered

-- Significantly lower variability of key PK and GD variables across

subjects

-- rHuPH20 in combination with Humulin demonstrated statistically

significant improvement across all parameters when compared to Humalog

alone

By making mealtime insulins faster, i.e., shifting insulin exposure and glucose lowering activity to earlier times and away from late postprandial times, combination with rHuPH20 yielded a profile of insulin kinetics and activity more like that of natural, endogenous prandial insulin release.

Diabetes mellitus is an increasingly prevalent, costly condition associated
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Inc. (NYSE: CRY ), a leading ... surgery, announced today that it has completed its ... and markets the HeRO (Hemodialysis Reliable Outflow) Graft, ... (ESRD) hemodialysis patients with limited access options and ...
... UBM Conferences , a division of UBM Plc (LSE: ... and Leachables Webinar to be hosted on May 17th, ... attend webinar will evaluate the considerations to be made ... in addition to highlighting how monomers and additives, such ...
Cached Medicine Technology:CryoLife Completes Acquisition of Hemosphere 2CryoLife Completes Acquisition of Hemosphere 3CryoLife Completes Acquisition of Hemosphere 4Global Webinar Focuses on Considerations for Extractables and Leachables 2
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... consent, many can,t recall details, study finds , WEDNESDAY, ... doctors doesn,t seem to help parents of children having ... procedures, researchers have found. , Before a child can ... what,s called informed consent. The process has four main ...
... ... Grand Opening Event Celebration at Azia Medical Spa in Birmingham, AL. , ... Birmingham, AL (PRWEB) March 17, 2010 -- Dee ... Azia Medical Spa will host a two day Grand Opening Celebration March 25 ...
... , March 17 Sleep HealthCenters has recently entered into a partnership with Milton Hospital, an affiliate ... Beginning this month, Sleep HealthCenters will perform diagnostic sleep studies at Milton Hospital with plans to open a clinic ... ... , ...
... of the pancreas is relatively rare. There are ... (PET), especially the non-functioning ones, in clinical and ... in the literature showed that the expression profiles ... in difficulty distinguishing the two entities. In recent ...
... integrated care, research shows , WEDNESDAY, March 17 (HealthDay ... them away from work can recover an average of four ... of rehabilitation program, a new study suggests. , Researchers in ... back pain who hadn,t been able to go to work ...
... Germany , March 17 Anatomist and ... Dr. Angelina Whalley present their new exhibition, ... ) , premiering at the Neunkirchen Zoo in ... holistic and sculptural anatomical menagerie, the display features the most revered ...
Cached Medicine News:Health News:Risks of Kids' Surgeries May Not Stick With Parents 2Health News:Azia Medical Spa in Birmingham, AL to Host Two Day Grand Opening Event March 25 and March 26, 2010. 2Health News:Azia Medical Spa in Birmingham, AL to Host Two Day Grand Opening Event March 25 and March 26, 2010. 3Health News:Sleep HealthCenters at Milton Hospital Now Open 2Health News:Sleep HealthCenters at Milton Hospital Now Open 3Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 2Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 3
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... BioSynthetic Mesh is a ... in the central section ... film of porcine collagen. ... the Avaulta™ BioSynthetic Mesh ...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
... Matrix delivers the advanced performance benefits ... and durability in a safe, permanent ... site-specific defect repair in pelvic floor ... porcine dermal collagen that readily incorporates ...
Medicine Products: